Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5221473 | 0.92 | TDP1 (0.66) | KMT2ATDP1L3MBTL1ADRB2ADRB1 | |
| SCHEMBL7905955 | 0.92 | KMT2A (0.71) | KMT2ATDP1L3MBTL1ADRB2ADRB1 | |
| SCHEMBL12255182 | 0.91 | SMPD1 (0.64) | KMT2ATDP1L3MBTL1ADRB2ADRB1 | |
| SCHEMBL15766601 | 0.90 | SMPD1 (0.67) | KMT2ATDP1L3MBTL1MEN1POLB | |
| SCHEMBL22438949 | 0.90 | SMPD1 (0.67) | KMT2ATDP1L3MBTL1MEN1POLB | |
| SCHEMBL15766529 | 0.90 | SMPD1 (0.67) | KMT2ATDP1L3MBTL1MEN1POLB | |
| SCHEMBL1989713 | 0.89 | KMT2A (0.62) | KMT2ATDP1L3MBTL1MEN1POLB | |
| SCHEMBL2473808 | 0.88 | L3MBTL1 (0.60) | KMT2ATDP1L3MBTL1ADRB2ADRB1 | |
| SCHEMBL9937950 | 0.88 | L3MBTL1 (0.60) | KMT2ATDP1L3MBTL1ADRB2ADRB1 | |
| SCHEMBL15344609 | 0.88 | KMT2A (0.66) | KMT2ATDP1L3MBTL1ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102834420-B | Internal and external donor compounds for olefin polymerization catalysts ii | BASF CORP. (US) | 2014-10-22 | — | — | CN | claimed |
| US-8569195-B2 | Internal and external donor compounds for olefin polymerization catalysts II | BASF CORPORATION (US) | 2013-10-29 | — | — | US | claimed |
| CN-102834420-A | Internal and external donor compounds for olefin polymerization catalysts ii | BASF CORP | 2012-12-19 | — | — | CN | claimed |
| CN-105612158-B | The somatostatin receptor hypotype 5 (SSTR5) antagonist | 武田药品工业株式会社 | 2017-06-30 | — | — | CN | disclosed |
| EP-2782938-B1 | HIGH ACTIVITY CATALYST FOR OLEFIN POLYMERIZATION | BASF CORP (US) | 2016-08-31 | — | — | EP | disclosed |
| CN-105612158-A | Antagonists of somatostatin receptor subtype 5 (sstr5) | TAKEDA PHARMACEUTICALS CO | 2016-05-25 | — | — | CN | disclosed |
| CN-102834420-B | Internal and external donor compounds for olefin polymerization catalysts ii | BASF CORP. (US) | 2014-10-22 | — | — | CN | disclosed |
| CN-102834420-A | Internal and external donor compounds for olefin polymerization catalysts ii | BASF CORP | 2012-12-19 | — | — | CN | disclosed |
| US-20120183660-A1 | ISOMANNIDE DERIVATIVES AND THEIR USE AS TASTANTS | SENOMYX, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2448944-A2 | ISOMANNIDE DERIVATIVES AND THEIR USE AS TASTANTS | Senomyx, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002871-A2 | ISOMANNIDE DERIVATIVES AND THEIR USE AS TASTANTS | SENOMYX, INC (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120183660-A1 | ISOMANNIDE DERIVATIVES AND THEIR USE AS TASTANTS | TAS2R41, TAS2R42, TAS2R40 | KMT2A 3094/4885TDP1 3692/4885L3MBTL1 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.